Exhibit 4.8
NOL PRESERVATION LOCK-UP
AGREEMENT
This NOL PRESERVATION LOCK-UP
AGREEMENT (this “ Agreement ”) is made effective
as of the Effective Date between Jazz Pharmaceuticals, Inc., a
Delaware corporation (the “ Company ”), and the
several investor signatories listed on Schedule A hereto
(including any successor or assign of any such investor, each an
“ Investor ” and collectively, the “
Investors ”).
WHEREAS, the Company and each
Investor deems it to be in the best interests of the Company to
enter into this Agreement, to restrict transferability of such
Investor’s Company capital stock in order to minimize the
risk that the Company will undergo an “ownership
change” within the meaning of Section 382(g) of the Code
that would subject use of its Tax Benefits to limitation under
Section 382(a) of the Code.
NOW, THEREFORE, in consideration of
the premises and the covenants and agreements hereinafter set
forth, the parties hereby agree as follows:
Section I
Definitions
1.1 As used in this
Agreement:
“ Acquire ” or
“ Acquisition ” means the acquisition of record,
legal, beneficial or any other ownership of Company Securities by
any means, including, without limitation, (a) a purchase of
Company Securities from the owner thereof, whether effected through
a private sale, an open market transaction, or otherwise,
(b) the exercise of any rights under any option, warrant,
convertible security, pledge or other security interest or similar
right to acquire Company Securities, or (c) the entering into
of any swap, hedge or other arrangement that results in the
acquisition of any of the economic consequences of ownership of
Company Securities, but shall not in the case of clauses
(a) – (c) include any acquisition unless, as a
result, the acquirer would be considered an owner of such Company
Securities for United States federal income tax
purposes.
“ Business Day ”
means a day, other than a Saturday or Sunday, on which banks in New
York City are open for the general transaction of
business.
“ Code ” means
the Internal Revenue Code of 1986, as amended.
“ Company Securities
” means (a) shares of Common Stock of the Company,
(b) shares of Preferred Stock of the Company of any class or
series, (c) any other interests in the Company not already
described in clauses (a) or (b) that constitute
“stock” of the Company pursuant to Treasury Regulation
Section 1.382-2T(f)(18), and (d) warrants, options or
other rights to purchase stock of the Company (including interests
described in Treasury Regulations
Section 1.382-2T(h)(4)(v)).
1
“ Effective Date
” means the date upon which the last signature of each of the
Investors listed on Schedule A hereto has been delivered to
the Company.
“ Entity ” means
an entity within the meaning of Treasury Regulation
Section 1.382-3(a)(1).
“ Fundamental
Transaction ” means (i) any consolidation or merger
of the Company with or into any other corporation or other entity
or person, or any other corporate reorganization, in which the
stockholders of the Company immediately prior to such
consolidation, merger or reorganization own less than 50% of the
voting power of the surviving entity immediately after such
consolidation, merger or reorganization, or (ii) the sale,
transfer or other disposition of all or substantially all of the
Company’s assets to another entity.
“ Person ” means
an individual, corporation, estate, trust, association, limited
liability company, partnership, joint venture or similar
organization, and also includes a syndicate or group as those terms
are used for the purposes of Section 13(d)(3) of the
Securities Exchange Act of 1934, as amended.
“ Restriction Release
Date ” means the earlier of (i) June 24, 2011,
(ii) immediately prior to the consummation of a Fundamental
Transaction, (iii) such date as all Investors shall agree in
writing to terminate this Agreement or (iv) such date on which
the Company in its sole judgment determines the restrictions
contained in this Agreement are no longer needed and thereupon
notifies the Investors in writing that the restrictions set forth
in this Agreement shall terminate.
“ Restricted Activity
” means (i) the Acquisition of additional Company
Securities by an Investor, (ii) the Transfer of any Company
Securities currently owned by such Investor or entering into any
agreements for such Transfer, (iii) distributing any Company
Securities held by an Investor that is an Entity to such
Investor’s owners, or (iv) exercising any warrants or
other rights to acquire Company stock described in clause
(d) of the definition of Company Securities.
“ Tax Benefits ”
means the net operating loss carryovers, capital loss carryovers,
general business credit carryovers, alternative minimum tax credit
carryovers and foreign tax credit carryovers, as well as any
“net unrealized built-in loss” within the meaning of
Section 382 of the Code, of the Company, any direct or
indirect subsidiary thereof, or any consolidated or combined tax
filing group of which the Company is a member.
“ Transfer ”
means any direct or indirect, sale, transfer, assignment,
conveyance, pledge or other disposition of Company Securities in
any manner whatsoever, whether voluntary or involuntary, by
operation of law or otherwise, or any attempt to do any of the
foregoing. A Transfer shall also include the creation or grant of
an option (including within the meaning of Treasury Regulation
Section 1.382-2T(h)(4)(v)).
“ Treasury Regulation
” means a Treasury Regulation promulgated under the
Code.
1.2 Other defined terms shall have
the meanings assigned to them in the preamble to this Agreement or
as defined elsewhere in this Agreement.
2
Section II
Restrictions on Stock held by the
Investors
2.1 Approval Required for
Restricted Activities . From and after the Effective Date and
prior to the Restriction Release Date, each Investor hereby agrees
that it will not engage in any Restricted Activity without first
obtaining the approval of Company in the manner set forth in this
Section II. Any purported Transfer made in violation of this
Section 2.1 shall be null and void and shall not be effective
to Transfer any record, legal, beneficial or any other ownership of
the Company Securities in respect of such purported Transfer to any
transferee thereof.
2.2 Request for Approval .
The restrictions contained in this Agreement are for the purpose of
minimizing the risk that any “ownership change” (as
defined in Section 382(g) of the Code) with respect to the
Company may limit the Company’s ability to utilize its Tax
Benefits. In connection therewith, if an Investor proposes to
undertake a Restricted Activity, it shall, not less than ten
(10) Business Days prior to the date of the proposed
Restricted Activity, request in writing (a “ Request
”) that the Company review the proposed Restricted Activity
and authorize or not authorize the proposed Restricted Activity in
accordance with this Section II. A Request shall be delivered in
accordance with the Notice provisions of Section 4.11. Such
Request shall be deemed to have been received by the Company when
actually received by the Company. A Request shall include
(i) the name, address and telephone number of such requesting
Investor, (ii) a description of the Restricted Activity that
such Investor proposes to undertake, (iii) the date on which
the proposed Restricted Activity is expected to take place (or, if
the proposed Restricted Activity consists of a transaction on a
national securities exchange or any national securities quotation
system, a statement to that effect), (iv) the name of the
counter party (or parties) to the proposed Restricted Activity (or,
if the proposed Restricted Activity consists of a transaction on a
national securities exchange or any national securities quotation
system, a statement to that effect) and (v) a request that the
Company approve the proposed Restricted Activity pursuant to this
Section II.
2.3 Approval by the Company .
The Company may authorize a proposed Restricted Activity, if it
determines, in its reasonable judgment, that the proposed
Restricted Activity, when coupled with other Restricted Activities,
if any, proposed or expected to be proposed by other Company
stockholders, would not be likely to result in an ownership
change within the meaning of Section 382(g) of the Code that
would be likely to limit the Company’s ability to utilize its
Tax Benefits. The Company may, in its sole discretion, impose any
conditions that it deems reasonable and appropriate in connection
with authorizing any such proposed Restricted Activity by an
Investor. In addition, the Company may, in its sole discretion,
require such representations from such Investor or such opinions of
counsel to be rendered by counsel selected or approved by the
Company and at its expense, in each case as to such matters as the
Company may determine. The Company shall approve or disapprove a
Request on or before the tenth (10 th ) Business Day following the
Company’s receipt thereof.
3
Section III
Certain Remedies
3.1 Treatment of Unapproved
Restricted Activity . The parties acknowledge and agree that no
employee or agent of the Company (including any transfer agent or
registrar of the Company) shall record any purported Transfer that
is made in violation of Section II, and the purported transferee of
any such purported Transfer shall not be recognized as a
stockholder of the Company for any purpose whatsoever in respect of
the Company Securities that are the subject thereof. The purported
transferee of a Transfer that is made in violation of Section II
shall not be entitled with respect to such Company Securities to
any rights of an owner thereof, including without limitation, any
right to vote, or to receive dividends or distributions, in respect
thereof, and the Company shall be entitled to so instruct its
transfer agent or registrar of the same.
3.2 Injunctions . Each
Investor acknowledges that irreparable damage would occur in the
event that any of the provisions of this Agreement were not
performed in accordance with its specified terms or were otherwise
breached. The Company shall be entitled to an injunction or
injunctions to prevent breaches of the provisions of this Agreement
and to enforce specifically the terms and provisions hereof in any
court having jurisdiction, such remedy being in addition to any
other remedy to which the Company may be entitled at law or
equity.
Section IV
Miscellaneous
4.1 Powers of the Board of
Directors . Nothing contained in this Agreement shall limit the
authority of the Board of Directors of the Company to take such
other action to the extent permitted by law as it deems necessary
or advisable to preserve the Company’s Tax Benefits. The
Board of Directors of the Company shall have the power to determine
all matters necessary for determining compliance with this
Agreement. In the case of an ambiguity in the application of any of
the provisions of this Agreement, including any definition used
herein, the Board of Directors shall have the power to determine
the application of such provisions with respect to any situation
based on its reasonable belief, understanding or knowledge of the
circumstances. In the event that this Agreement requires an action
by the Board of Directors but fails to provide specific guidance
with respect to such action, the Board of Directors shall have the
power to determine the action to be taken so long as such action is
not contrary to the provisions of this Agreement. All such actions,
calculations, interpretations and determinations that are done or
made by the Board of Directors in good faith shall be final,
conclusive and binding on the Company, and each Investor; provided,
however, that the Board of Directors may delegate all or any
portion of its duties and powers under this Agreement to a
committee of the Board of Directors as it deems advisable or
necessary.
4.2 Legends . All
certificates reflecting Company Securities subject to this
Agreement on or after the Effective Date shall, until the
Restriction Release Date, bear a conspicuous legend in
substantially the following form:
[THIS SECURITY AND THE SECURITIES
ISSUABLE UPON EXERCISE OR CONVERSION OF THIS SECURITY] [THESE
SECURITIES] ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND CERTAIN OTHER RESTRICTIONS, [INCLUDING EXERCISE
OR
4
CONVERSION RESTRICTIONS,] ALL AS SET
FORTH IN A NOL PRESERVATION LOCK-UP AGREEMENT BETWEEN JAZZ
PHARMACEUTICALS, INC. AND THE ORIGINAL HOLDER OF [THIS
SECURITY][THESE SECURITIES], A COPY OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICES OF JAZZ PHARMACEUTICALS, INC.
In order to give effect to the
foregoing, each Investor hereby agrees, immediately following the
Effective Date, to surrender to the Company or to the
Company’s transfer agent any Company Securities or
certificates representing Company Securities held by such Investor
(endorsed or with stock powers attached, signatures guaranteed if
so required by the Company’s transfer agent in the ordinary
course of business, and otherwise in form necessary to effect
reissuance) for the purpose of effecting the reissuance of such
Company Securities and certificates representing Company Securities
containing the above legend.
The Company shall have the power to
make appropriate notations upon its stock transfer records and to
instruct any transfer agent, registrar, securities intermediary or
depository with respect to the requirements of this Agreement for
any uncertificated Company Securities or Company Securities held in
an indirect holding system.
4.3 Entire Agreement . This
Agreement constitutes and contains the entire agreement and
understanding of the Parties with respect to the subject matter
hereof and supersedes any and all prior negotiations,
correspondence, agreements, understandings, duties or obligations
between the Parties with respect to the subject matter
hereof.
4.4 Amendments; Waivers . No
provision of this Agreement may be waived or amended except in a
written instrument signed by each of the Company and each Investor.
No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a
waiver of any other provision, condition or requirement hereof, nor
shall any delay or omission of any party to exercise any right
hereunder in any manner impair the exercise of any such
right.
4.5 Severability . If any
provision of this Agreement is held to be invalid or unenforceable
in any respect, the validity and enforceability of the remaining
terms and provisions of this Agreement shall not in any way be
affected or impaired thereby and the parties will attempt to agree
upon a valid and enforceable provision that is a reasonable
substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.
4.6 Governing Law . All
questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of
Delaware, without regard to the principles of conflicts of law
thereof.
4.7 Counterparts . This
Agreement may be executed and delivered in one or more
counterparts, and by the different parties hereto in separate
counterparts, each of which, when executed and delivered, shall be
deemed to be an original but all of which taken together shall
constitute one and the same agreement. In the event that any
signature is delivered by facsimile
5
transmission, or by e-mail delivery of a
“.pdf” format data file, such signature shall create a
valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an
original thereof.
4.8 Representations of the
Parties . Each party hereto represents and warrants that the
execution, delivery and performance by such party of the
transactions contemplated by this Agreement have been duly
authorized by all necessary corporate or, if such party is not a
corporation, such partnership, limited liability company or other
applicable like action, on the part of such party. This Agreement
has been duly executed by such party, and when delivered by such
party in accordance with the terms hereof, will constitute the
valid and legally binding obligation of such party, enforceable
against it in accordance with its terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general
application.
4.9 Independent Nature of
Investor Obligations . The obligations of each Investor under
this Agreement are several and not joint with the obligations of
any other Investor, and no Investor shall be responsible in any way
for the performance of the obligations of any other Investor under
this Agreement. Notwithstanding the foregoing, this Agreement shall
not take effect unless and until all parties named on Schedule A
have executed, delivered and released their signature page(s)
hereto to the Company.
4.10 Captions . Titles or
captions of paragraphs contained in this Agreement are inserted
only as a matter of convenience and for reference, and in no way
define, limit, extend, or describe the scope of this Agreement or
the intent of any provision hereof.
4.11 Notices . Any and all
notices or other communications or deliveries required or permitted
to be provided hereunder shall be in writing and shall be deemed
given and effective on the earliest of (a) the date of
transmission, if such notice or communication is delivered via
facsimile (provided the sender receives a machine-generated
confirmation of successful transmission) at the facsimile number
specified in this Section 4.11 prior to 5:00 p.m., Pacific
Time, on a Business Day, except in the event that the recipient is
located outside the United States, in which case notice shall be
deemed given and effective on the next Business Day after the date
of transmission, (b) the next Business Day after the date of
transmission, if such notice or communication is delivered via
facsimile at the facsimile number specified in this Section on a
day that is not a Business Day or later than 5:00 p.m., Pacific
Time, on any Business Day, (c) the Business Day following the
date of mailing, if sent by U.S. nationally recognized overnight
courier service with next day delivery specified, or in the event
the recipient is located outside the United States, five
(5) Business Day following the date of mailing, if sent by
internationally recognized overnight courier service with next day
delivery specified, or (d) upon actual receipt by the party to
whom such notice is required to be given. The address for such
notices and communications shall be as follows:
If to the Company
:
Jazz Pharmaceuticals,
Inc.
3180 Porter Drive
Palo Alto, California
94304
Attention: General
Counsel
Fax: (650) 496-3781
6
With a copy to (which shall not
constitute notice):
Cooley Godward Kronish
LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, California
94306-2155
Attention: Suzanne Sawochka Hooper,
Esq.
Fax: (650) 849-7400
If to an Investor
: At the address set forth on its
respective signature page attached hereto, or such other address as
such Investor may designate by ten (10) days advance written
notice to the other parties hereto.
[Signature Pages Follow]
7
IN WITNESS WHEREOF,
the parties hereto have executed
this NOL Preservation Lock-Up Agreement effective as of the
Effective Date.
|
|
|
|
JAZZ
PHARMACEUTICALS, INC.,
|
|
a Delaware
corporation
|
|
|
|
By:
|
|
|
|
|
Bruce C.
Cozadd
|
|
|
Chief Executive
Officer
|
|
|
|
Date:
|
|
|
IN WITNESS WHEREOF,
the parties hereto have executed
this NOL Preservation Lock-Up Agreement effective as of the
Effective Date.
INVESTORS: